Harvard expert quits US FDA panel as furore over Biogen's Alzheimer's drug grows

61
17
Favorite

Harvard expert quits US FDA panel as furore over Biogen's Alzheimer's drug grows

The Straits Times2021-06-11

WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food and Drug Administration advisory panel in protest over the agency's decision to approve Biogen's ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（17）

Endlesstory
·2021-06-12
Nicea
Reply
Like
Report
Longshot
·2021-06-11
Nice
Reply
Like
Report
GuyNextDoor
·2021-06-11
Amazing
Reply
Like
Report
CWJ
·2021-06-11
?
Reply
Like
Report
Bryan_lyc
·2021-06-11
Cool
Reply
Like
Report
Alfred1007
·2021-06-11
Respect! More studies should be conducted before they granted approval..
Reply
Like
Report
RichTea
·2021-06-11
Okay
Reply
Like
Report
jaffer
·2021-06-11
In the money trap
Reply
Like
Report
JamesPang
·2021-06-11
That is the problem with government agency.. they think they know everything
Reply
5
Report
Lanying
·2021-06-11
O
Reply
2
Report
Fold Replies
- Lanying:
  O
  2021-06-11
  Reply
  Report
CharlesKing
·2021-06-11
Like and comment plz???
Reply
5
Report
Fold Replies
- 木吉蒂:
  done
  2021-06-11
  Reply
  Report
GCL08
·2021-06-11
Respect to stick to do the right thing for a better world rather for companies to make a quick buck by approving drugs that are not ready ??❤️?✌️
Reply
3
Report
Fold Replies
- Qkuca:
  [微笑]
  2021-06-11
  Reply
  Report
nickname223
·2021-06-11
Like
Reply
4
Report
Dickson8614
·2021-06-11
Please like and comment
Reply
5
Report
Fold Replies
- nickname223:
  loke
  2021-06-11
  Reply
  Report
- edamame:
  up
  2021-06-11
  Reply
  Report
Mayvee
·2021-06-11
Must be a subjective type of decision made for the approval hence a resignation took place.
Reply
4
Report
Fold Replies
- Qkuca:
  [微笑]
  2021-06-11
  Reply
  Report
edamame
·2021-06-11
Wow
Reply
3
Report
Sena11
·2021-06-11
Pls like
Reply
2
Report
Fold Replies
- Sena11:
  Thank
  2021-06-11
  Reply
  Report
- edamame:
  up
  2021-06-11
  Reply
  Report
- TeckLeong:
  Pls like aNd comMent back
  2021-06-11
  Reply
  Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2142346278?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-06-11 08:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2142346278","market":"us","top_or_hot":-1,"title":"Harvard expert quits US FDA panel as furore over Biogen's Alzheimer's drug grows","media":"The Straits Times","content":"<div>\n<p>WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food and Drug Administration advisory panel in protest over the agency's decision to approve Biogen's ...</p>\n\n<a href=\"http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows\">Source Link</a>\n\n</div>\n","source":"straits_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Harvard expert quits US FDA panel as furore over Biogen's Alzheimer's drug grows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHarvard expert quits US FDA panel as furore over Biogen's Alzheimer's drug grows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 08:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows><strong>The Straits Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food and Drug Administration advisory panel in protest over the agency's decision to approve Biogen's ...</p>\n\n<a href=\"http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BIIB","symbol_name":"渤健公司","start_time":0,"source_url":"http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows","article_id":"2142346278","we_media_id":null,"thumbnails":[],"rights":{"source":"straits_highlight","url":"http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows","rn_cache_url":null,"customStyle":"","selectors":"body","filters":"","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2142346278","pubTimestamp":1623372873,"sourceInfo":{"source_id":"straits_highlight","name":"Straits Times"},"weMediaInfo":null,"summary":"WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food an","collect":0,"end_time":0,"defaultTopTitle":"straitstimes.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BIIB":"渤健公司"},"translate_title":"哈佛专家退出美国食品和药物管理局专家组，因生化基因的阿兹海默症药物引起的愤怒与日俱增","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIIB":0.9},"content_text":"WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food and Drug Administration advisory panel in protest over the agency's decision to approve Biogen's Alzheimer's drug Aduhelm.\nThe doctor, Aaron Kesselheim, announced his departure in a letter to FDA Acting Commissioner Janet Woodcock. He is the third committee member to quit in the wake of the highly controversial approval.\nTwo big trials of the drug produced conflicting results on whether it could slow cognitive decline. The advisory panel voted almost unanimously in November that a single trial wasn't enough to conclude that the drug works.\nBut the FDA granted conditional approval to the drug on Monday (June 7), on the basis that it could remove a bad protein called amyloid from the brain.\nThe decision \"was probably the worst drug approval decision in recent US history,\" Dr Kesselheim said in the letter. \"The agency owes it to the nation to provide a detailed justification\" for going against the advice of the panel, he said.\nDuring the November advisory committee meeting, concerns about the data \"were not given adequate time for discussion\" and the crucial question of whether an Alzheimer's drug should be approved based on amyloid lowering alone \"was specifically excluded from discussion,\" Dr Kesselheim wrote.\nThe doctor also made broader criticisms of the agency, saying it needed to reassess its decision-making process.\nDr Kesselheim is the third member to quit the committee, following Joel Perlmutter from the Washington University School of Medicine and David Knopman from the Mayo Clinic. Both Dr Perlmutter and Dr Kesselheim voted against the drug, while Dr Knopman was recused from the November hearing as he had already staked out a public position critical of the drug's trial results.\nDr Perlmutter resigned \"due to the FDA approval of aducanumab without further discussion with the advisory panel,\" a spokeswoman for Washington University said in an e-mail.\nDr Knopman's resignation was confirmed by the Mayo Clinic.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":188813536,"gmtCreate":1623427586025,"gmtModify":1704203545173,"author":{"id":"3582053750057944","authorId":"3582053750057944","name":"Endlesstory","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3582053750057944","authorIdStr":"3582053750057944"},"htmlText":"Nicea&nbsp;","listText":"Nicea&nbsp;","text":"Nicea","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/188813536","repostId":2142346278,"repostType":4,"repost":{"id":"2142346278","pubTimestamp":1623372873,"share":"https://ttm.financial/m/news/2142346278?lang=&edition=fundamental","pubTime":"2021-06-11 08:54","market":"us","language":"en","title":"Harvard expert quits US FDA panel as furore over Biogen's Alzheimer's drug grows","url":"https://stock-news.laohu8.com/highlight/detail?id=2142346278","media":"The Straits Times","summary":"WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food an","content":"<div>\n<p>WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food and Drug Administration advisory panel in protest over the agency's decision to approve Biogen's ...</p>\n\n<a href=\"http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows\">Web Link</a>\n\n</div>\n","source":"straits_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Harvard expert quits US FDA panel as furore over Biogen's Alzheimer's drug grows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHarvard expert quits US FDA panel as furore over Biogen's Alzheimer's drug grows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 08:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows><strong>The Straits Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food and Drug Administration advisory panel in protest over the agency's decision to approve Biogen's ...</p>\n\n<a href=\"http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142346278","content_text":"WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food and Drug Administration advisory panel in protest over the agency's decision to approve Biogen's Alzheimer's drug Aduhelm.\nThe doctor, Aaron Kesselheim, announced his departure in a letter to FDA Acting Commissioner Janet Woodcock. He is the third committee member to quit in the wake of the highly controversial approval.\nTwo big trials of the drug produced conflicting results on whether it could slow cognitive decline. The advisory panel voted almost unanimously in November that a single trial wasn't enough to conclude that the drug works.\nBut the FDA granted conditional approval to the drug on Monday (June 7), on the basis that it could remove a bad protein called amyloid from the brain.\nThe decision \"was probably the worst drug approval decision in recent US history,\" Dr Kesselheim said in the letter. \"The agency owes it to the nation to provide a detailed justification\" for going against the advice of the panel, he said.\nDuring the November advisory committee meeting, concerns about the data \"were not given adequate time for discussion\" and the crucial question of whether an Alzheimer's drug should be approved based on amyloid lowering alone \"was specifically excluded from discussion,\" Dr Kesselheim wrote.\nThe doctor also made broader criticisms of the agency, saying it needed to reassess its decision-making process.\nDr Kesselheim is the third member to quit the committee, following Joel Perlmutter from the Washington University School of Medicine and David Knopman from the Mayo Clinic. Both Dr Perlmutter and Dr Kesselheim voted against the drug, while Dr Knopman was recused from the November hearing as he had already staked out a public position critical of the drug's trial results.\nDr Perlmutter resigned \"due to the FDA approval of aducanumab without further discussion with the advisory panel,\" a spokeswoman for Washington University said in an e-mail.\nDr Knopman's resignation was confirmed by the Mayo Clinic.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":188080554,"gmtCreate":1623416184478,"gmtModify":1704203009945,"author":{"id":"3570092809336734","authorId":"3570092809336734","name":"Longshot","avatar":"https://static.tigerbbs.com/7cad4ddeab0622dd29ed1d7c76c750b8","vip":1,"hat":"https://static.tigerbbs.com/306aa047bc14b6942cda1aed925cf8c3","crmLevel":7,"crmLevelSwitch":0,"idStr":"3570092809336734","authorIdStr":"3570092809336734"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/188080554","repostId":2142346278,"repostType":4,"repost":{"id":"2142346278","pubTimestamp":1623372873,"share":"https://ttm.financial/m/news/2142346278?lang=&edition=fundamental","pubTime":"2021-06-11 08:54","market":"us","language":"en","title":"Harvard expert quits US FDA panel as furore over Biogen's Alzheimer's drug grows","url":"https://stock-news.laohu8.com/highlight/detail?id=2142346278","media":"The Straits Times","summary":"WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food an","content":"<div>\n<p>WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food and Drug Administration advisory panel in protest over the agency's decision to approve Biogen's ...</p>\n\n<a href=\"http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows\">Web Link</a>\n\n</div>\n","source":"straits_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Harvard expert quits US FDA panel as furore over Biogen's Alzheimer's drug grows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHarvard expert quits US FDA panel as furore over Biogen's Alzheimer's drug grows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 08:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows><strong>The Straits Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food and Drug Administration advisory panel in protest over the agency's decision to approve Biogen's ...</p>\n\n<a href=\"http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142346278","content_text":"WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food and Drug Administration advisory panel in protest over the agency's decision to approve Biogen's Alzheimer's drug Aduhelm.\nThe doctor, Aaron Kesselheim, announced his departure in a letter to FDA Acting Commissioner Janet Woodcock. He is the third committee member to quit in the wake of the highly controversial approval.\nTwo big trials of the drug produced conflicting results on whether it could slow cognitive decline. The advisory panel voted almost unanimously in November that a single trial wasn't enough to conclude that the drug works.\nBut the FDA granted conditional approval to the drug on Monday (June 7), on the basis that it could remove a bad protein called amyloid from the brain.\nThe decision \"was probably the worst drug approval decision in recent US history,\" Dr Kesselheim said in the letter. \"The agency owes it to the nation to provide a detailed justification\" for going against the advice of the panel, he said.\nDuring the November advisory committee meeting, concerns about the data \"were not given adequate time for discussion\" and the crucial question of whether an Alzheimer's drug should be approved based on amyloid lowering alone \"was specifically excluded from discussion,\" Dr Kesselheim wrote.\nThe doctor also made broader criticisms of the agency, saying it needed to reassess its decision-making process.\nDr Kesselheim is the third member to quit the committee, following Joel Perlmutter from the Washington University School of Medicine and David Knopman from the Mayo Clinic. Both Dr Perlmutter and Dr Kesselheim voted against the drug, while Dr Knopman was recused from the November hearing as he had already staked out a public position critical of the drug's trial results.\nDr Perlmutter resigned \"due to the FDA approval of aducanumab without further discussion with the advisory panel,\" a spokeswoman for Washington University said in an e-mail.\nDr Knopman's resignation was confirmed by the Mayo Clinic.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":188080912,"gmtCreate":1623416152036,"gmtModify":1704203008973,"author":{"id":"3581591949899474","authorId":"3581591949899474","name":"GuyNextDoor","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581591949899474","authorIdStr":"3581591949899474"},"htmlText":"Amazing&nbsp;","listText":"Amazing&nbsp;","text":"Amazing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/188080912","repostId":2142346278,"repostType":4,"repost":{"id":"2142346278","pubTimestamp":1623372873,"share":"https://ttm.financial/m/news/2142346278?lang=&edition=fundamental","pubTime":"2021-06-11 08:54","market":"us","language":"en","title":"Harvard expert quits US FDA panel as furore over Biogen's Alzheimer's drug grows","url":"https://stock-news.laohu8.com/highlight/detail?id=2142346278","media":"The Straits Times","summary":"WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food an","content":"<div>\n<p>WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food and Drug Administration advisory panel in protest over the agency's decision to approve Biogen's ...</p>\n\n<a href=\"http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows\">Web Link</a>\n\n</div>\n","source":"straits_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Harvard expert quits US FDA panel as furore over Biogen's Alzheimer's drug grows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHarvard expert quits US FDA panel as furore over Biogen's Alzheimer's drug grows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 08:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows><strong>The Straits Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food and Drug Administration advisory panel in protest over the agency's decision to approve Biogen's ...</p>\n\n<a href=\"http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142346278","content_text":"WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food and Drug Administration advisory panel in protest over the agency's decision to approve Biogen's Alzheimer's drug Aduhelm.\nThe doctor, Aaron Kesselheim, announced his departure in a letter to FDA Acting Commissioner Janet Woodcock. He is the third committee member to quit in the wake of the highly controversial approval.\nTwo big trials of the drug produced conflicting results on whether it could slow cognitive decline. The advisory panel voted almost unanimously in November that a single trial wasn't enough to conclude that the drug works.\nBut the FDA granted conditional approval to the drug on Monday (June 7), on the basis that it could remove a bad protein called amyloid from the brain.\nThe decision \"was probably the worst drug approval decision in recent US history,\" Dr Kesselheim said in the letter. \"The agency owes it to the nation to provide a detailed justification\" for going against the advice of the panel, he said.\nDuring the November advisory committee meeting, concerns about the data \"were not given adequate time for discussion\" and the crucial question of whether an Alzheimer's drug should be approved based on amyloid lowering alone \"was specifically excluded from discussion,\" Dr Kesselheim wrote.\nThe doctor also made broader criticisms of the agency, saying it needed to reassess its decision-making process.\nDr Kesselheim is the third member to quit the committee, following Joel Perlmutter from the Washington University School of Medicine and David Knopman from the Mayo Clinic. Both Dr Perlmutter and Dr Kesselheim voted against the drug, while Dr Knopman was recused from the November hearing as he had already staked out a public position critical of the drug's trial results.\nDr Perlmutter resigned \"due to the FDA approval of aducanumab without further discussion with the advisory panel,\" a spokeswoman for Washington University said in an e-mail.\nDr Knopman's resignation was confirmed by the Mayo Clinic.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":181479956,"gmtCreate":1623409336675,"gmtModify":1704202811014,"author":{"id":"3558675003296714","authorId":"3558675003296714","name":"CWJ","avatar":"https://static.tigerbbs.com/9937d56ebf8e20a8ef7da0b626eeaddd","vip":1,"crmLevel":4,"crmLevelSwitch":1,"idStr":"3558675003296714","authorIdStr":"3558675003296714"},"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/181479956","repostId":2142346278,"repostType":4,"repost":{"id":"2142346278","pubTimestamp":1623372873,"share":"https://ttm.financial/m/news/2142346278?lang=&edition=fundamental","pubTime":"2021-06-11 08:54","market":"us","language":"en","title":"Harvard expert quits US FDA panel as furore over Biogen's Alzheimer's drug grows","url":"https://stock-news.laohu8.com/highlight/detail?id=2142346278","media":"The Straits Times","summary":"WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food an","content":"<div>\n<p>WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food and Drug Administration advisory panel in protest over the agency's decision to approve Biogen's ...</p>\n\n<a href=\"http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows\">Web Link</a>\n\n</div>\n","source":"straits_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Harvard expert quits US FDA panel as furore over Biogen's Alzheimer's drug grows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHarvard expert quits US FDA panel as furore over Biogen's Alzheimer's drug grows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 08:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows><strong>The Straits Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food and Drug Administration advisory panel in protest over the agency's decision to approve Biogen's ...</p>\n\n<a href=\"http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142346278","content_text":"WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food and Drug Administration advisory panel in protest over the agency's decision to approve Biogen's Alzheimer's drug Aduhelm.\nThe doctor, Aaron Kesselheim, announced his departure in a letter to FDA Acting Commissioner Janet Woodcock. He is the third committee member to quit in the wake of the highly controversial approval.\nTwo big trials of the drug produced conflicting results on whether it could slow cognitive decline. The advisory panel voted almost unanimously in November that a single trial wasn't enough to conclude that the drug works.\nBut the FDA granted conditional approval to the drug on Monday (June 7), on the basis that it could remove a bad protein called amyloid from the brain.\nThe decision \"was probably the worst drug approval decision in recent US history,\" Dr Kesselheim said in the letter. \"The agency owes it to the nation to provide a detailed justification\" for going against the advice of the panel, he said.\nDuring the November advisory committee meeting, concerns about the data \"were not given adequate time for discussion\" and the crucial question of whether an Alzheimer's drug should be approved based on amyloid lowering alone \"was specifically excluded from discussion,\" Dr Kesselheim wrote.\nThe doctor also made broader criticisms of the agency, saying it needed to reassess its decision-making process.\nDr Kesselheim is the third member to quit the committee, following Joel Perlmutter from the Washington University School of Medicine and David Knopman from the Mayo Clinic. Both Dr Perlmutter and Dr Kesselheim voted against the drug, while Dr Knopman was recused from the November hearing as he had already staked out a public position critical of the drug's trial results.\nDr Perlmutter resigned \"due to the FDA approval of aducanumab without further discussion with the advisory panel,\" a spokeswoman for Washington University said in an e-mail.\nDr Knopman's resignation was confirmed by the Mayo Clinic.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":181429368,"gmtCreate":1623407987154,"gmtModify":1704202772056,"author":{"id":"3565920966285810","authorId":"3565920966285810","name":"Bryan_lyc","avatar":"https://static.tigerbbs.com/66a10601cf8b6aaa3feafd891bc9778e","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3565920966285810","authorIdStr":"3565920966285810"},"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/181429368","repostId":2142346278,"repostType":4,"repost":{"id":"2142346278","pubTimestamp":1623372873,"share":"https://ttm.financial/m/news/2142346278?lang=&edition=fundamental","pubTime":"2021-06-11 08:54","market":"us","language":"en","title":"Harvard expert quits US FDA panel as furore over Biogen's Alzheimer's drug grows","url":"https://stock-news.laohu8.com/highlight/detail?id=2142346278","media":"The Straits Times","summary":"WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food an","content":"<div>\n<p>WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food and Drug Administration advisory panel in protest over the agency's decision to approve Biogen's ...</p>\n\n<a href=\"http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows\">Web Link</a>\n\n</div>\n","source":"straits_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Harvard expert quits US FDA panel as furore over Biogen's Alzheimer's drug grows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHarvard expert quits US FDA panel as furore over Biogen's Alzheimer's drug grows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 08:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows><strong>The Straits Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food and Drug Administration advisory panel in protest over the agency's decision to approve Biogen's ...</p>\n\n<a href=\"http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142346278","content_text":"WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food and Drug Administration advisory panel in protest over the agency's decision to approve Biogen's Alzheimer's drug Aduhelm.\nThe doctor, Aaron Kesselheim, announced his departure in a letter to FDA Acting Commissioner Janet Woodcock. He is the third committee member to quit in the wake of the highly controversial approval.\nTwo big trials of the drug produced conflicting results on whether it could slow cognitive decline. The advisory panel voted almost unanimously in November that a single trial wasn't enough to conclude that the drug works.\nBut the FDA granted conditional approval to the drug on Monday (June 7), on the basis that it could remove a bad protein called amyloid from the brain.\nThe decision \"was probably the worst drug approval decision in recent US history,\" Dr Kesselheim said in the letter. \"The agency owes it to the nation to provide a detailed justification\" for going against the advice of the panel, he said.\nDuring the November advisory committee meeting, concerns about the data \"were not given adequate time for discussion\" and the crucial question of whether an Alzheimer's drug should be approved based on amyloid lowering alone \"was specifically excluded from discussion,\" Dr Kesselheim wrote.\nThe doctor also made broader criticisms of the agency, saying it needed to reassess its decision-making process.\nDr Kesselheim is the third member to quit the committee, following Joel Perlmutter from the Washington University School of Medicine and David Knopman from the Mayo Clinic. Both Dr Perlmutter and Dr Kesselheim voted against the drug, while Dr Knopman was recused from the November hearing as he had already staked out a public position critical of the drug's trial results.\nDr Perlmutter resigned \"due to the FDA approval of aducanumab without further discussion with the advisory panel,\" a spokeswoman for Washington University said in an e-mail.\nDr Knopman's resignation was confirmed by the Mayo Clinic.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":181262248,"gmtCreate":1623397128284,"gmtModify":1704202495221,"author":{"id":"3570656625926041","authorId":"3570656625926041","name":"Alfred1007","avatar":"https://static.tigerbbs.com/81d8406380cbc0525927f00a9510f2fa","vip":1,"hat":"https://static.tigerbbs.com/4c5ceab71416b120bab4604c0754b52a","crmLevel":2,"crmLevelSwitch":0,"idStr":"3570656625926041","authorIdStr":"3570656625926041"},"htmlText":"Respect! More studies should be conducted before they granted approval..","listText":"Respect! More studies should be conducted before they granted approval..","text":"Respect! More studies should be conducted before they granted approval..","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/181262248","repostId":2142346278,"repostType":4,"repost":{"id":"2142346278","pubTimestamp":1623372873,"share":"https://ttm.financial/m/news/2142346278?lang=&edition=fundamental","pubTime":"2021-06-11 08:54","market":"us","language":"en","title":"Harvard expert quits US FDA panel as furore over Biogen's Alzheimer's drug grows","url":"https://stock-news.laohu8.com/highlight/detail?id=2142346278","media":"The Straits Times","summary":"WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food an","content":"<div>\n<p>WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food and Drug Administration advisory panel in protest over the agency's decision to approve Biogen's ...</p>\n\n<a href=\"http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows\">Web Link</a>\n\n</div>\n","source":"straits_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Harvard expert quits US FDA panel as furore over Biogen's Alzheimer's drug grows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHarvard expert quits US FDA panel as furore over Biogen's Alzheimer's drug grows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 08:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows><strong>The Straits Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food and Drug Administration advisory panel in protest over the agency's decision to approve Biogen's ...</p>\n\n<a href=\"http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142346278","content_text":"WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food and Drug Administration advisory panel in protest over the agency's decision to approve Biogen's Alzheimer's drug Aduhelm.\nThe doctor, Aaron Kesselheim, announced his departure in a letter to FDA Acting Commissioner Janet Woodcock. He is the third committee member to quit in the wake of the highly controversial approval.\nTwo big trials of the drug produced conflicting results on whether it could slow cognitive decline. The advisory panel voted almost unanimously in November that a single trial wasn't enough to conclude that the drug works.\nBut the FDA granted conditional approval to the drug on Monday (June 7), on the basis that it could remove a bad protein called amyloid from the brain.\nThe decision \"was probably the worst drug approval decision in recent US history,\" Dr Kesselheim said in the letter. \"The agency owes it to the nation to provide a detailed justification\" for going against the advice of the panel, he said.\nDuring the November advisory committee meeting, concerns about the data \"were not given adequate time for discussion\" and the crucial question of whether an Alzheimer's drug should be approved based on amyloid lowering alone \"was specifically excluded from discussion,\" Dr Kesselheim wrote.\nThe doctor also made broader criticisms of the agency, saying it needed to reassess its decision-making process.\nDr Kesselheim is the third member to quit the committee, following Joel Perlmutter from the Washington University School of Medicine and David Knopman from the Mayo Clinic. Both Dr Perlmutter and Dr Kesselheim voted against the drug, while Dr Knopman was recused from the November hearing as he had already staked out a public position critical of the drug's trial results.\nDr Perlmutter resigned \"due to the FDA approval of aducanumab without further discussion with the advisory panel,\" a spokeswoman for Washington University said in an e-mail.\nDr Knopman's resignation was confirmed by the Mayo Clinic.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":181297292,"gmtCreate":1623395082416,"gmtModify":1704202440585,"author":{"id":"3580611966360609","authorId":"3580611966360609","name":"RichTea","avatar":"https://static.tigerbbs.com/17f24d7c1ce49657326aac3bf4f42040","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3580611966360609","authorIdStr":"3580611966360609"},"htmlText":"Okay","listText":"Okay","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/181297292","repostId":2142346278,"repostType":4,"repost":{"id":"2142346278","pubTimestamp":1623372873,"share":"https://ttm.financial/m/news/2142346278?lang=&edition=fundamental","pubTime":"2021-06-11 08:54","market":"us","language":"en","title":"Harvard expert quits US FDA panel as furore over Biogen's Alzheimer's drug grows","url":"https://stock-news.laohu8.com/highlight/detail?id=2142346278","media":"The Straits Times","summary":"WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food an","content":"<div>\n<p>WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food and Drug Administration advisory panel in protest over the agency's decision to approve Biogen's ...</p>\n\n<a href=\"http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows\">Web Link</a>\n\n</div>\n","source":"straits_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Harvard expert quits US FDA panel as furore over Biogen's Alzheimer's drug grows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHarvard expert quits US FDA panel as furore over Biogen's Alzheimer's drug grows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 08:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows><strong>The Straits Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food and Drug Administration advisory panel in protest over the agency's decision to approve Biogen's ...</p>\n\n<a href=\"http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142346278","content_text":"WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food and Drug Administration advisory panel in protest over the agency's decision to approve Biogen's Alzheimer's drug Aduhelm.\nThe doctor, Aaron Kesselheim, announced his departure in a letter to FDA Acting Commissioner Janet Woodcock. He is the third committee member to quit in the wake of the highly controversial approval.\nTwo big trials of the drug produced conflicting results on whether it could slow cognitive decline. The advisory panel voted almost unanimously in November that a single trial wasn't enough to conclude that the drug works.\nBut the FDA granted conditional approval to the drug on Monday (June 7), on the basis that it could remove a bad protein called amyloid from the brain.\nThe decision \"was probably the worst drug approval decision in recent US history,\" Dr Kesselheim said in the letter. \"The agency owes it to the nation to provide a detailed justification\" for going against the advice of the panel, he said.\nDuring the November advisory committee meeting, concerns about the data \"were not given adequate time for discussion\" and the crucial question of whether an Alzheimer's drug should be approved based on amyloid lowering alone \"was specifically excluded from discussion,\" Dr Kesselheim wrote.\nThe doctor also made broader criticisms of the agency, saying it needed to reassess its decision-making process.\nDr Kesselheim is the third member to quit the committee, following Joel Perlmutter from the Washington University School of Medicine and David Knopman from the Mayo Clinic. Both Dr Perlmutter and Dr Kesselheim voted against the drug, while Dr Knopman was recused from the November hearing as he had already staked out a public position critical of the drug's trial results.\nDr Perlmutter resigned \"due to the FDA approval of aducanumab without further discussion with the advisory panel,\" a spokeswoman for Washington University said in an e-mail.\nDr Knopman's resignation was confirmed by the Mayo Clinic.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":181382767,"gmtCreate":1623374266759,"gmtModify":1704201931916,"author":{"id":"3574309252756598","authorId":"3574309252756598","name":"jaffer","avatar":"https://static.tigerbbs.com/1a3d779d7e90da7a7b584e147536abf7","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3574309252756598","authorIdStr":"3574309252756598"},"htmlText":"In the money trap","listText":"In the money trap","text":"In the money trap","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/181382767","repostId":2142346278,"repostType":4,"repost":{"id":"2142346278","pubTimestamp":1623372873,"share":"https://ttm.financial/m/news/2142346278?lang=&edition=fundamental","pubTime":"2021-06-11 08:54","market":"us","language":"en","title":"Harvard expert quits US FDA panel as furore over Biogen's Alzheimer's drug grows","url":"https://stock-news.laohu8.com/highlight/detail?id=2142346278","media":"The Straits Times","summary":"WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food an","content":"<div>\n<p>WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food and Drug Administration advisory panel in protest over the agency's decision to approve Biogen's ...</p>\n\n<a href=\"http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows\">Web Link</a>\n\n</div>\n","source":"straits_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Harvard expert quits US FDA panel as furore over Biogen's Alzheimer's drug grows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHarvard expert quits US FDA panel as furore over Biogen's Alzheimer's drug grows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 08:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows><strong>The Straits Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food and Drug Administration advisory panel in protest over the agency's decision to approve Biogen's ...</p>\n\n<a href=\"http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142346278","content_text":"WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food and Drug Administration advisory panel in protest over the agency's decision to approve Biogen's Alzheimer's drug Aduhelm.\nThe doctor, Aaron Kesselheim, announced his departure in a letter to FDA Acting Commissioner Janet Woodcock. He is the third committee member to quit in the wake of the highly controversial approval.\nTwo big trials of the drug produced conflicting results on whether it could slow cognitive decline. The advisory panel voted almost unanimously in November that a single trial wasn't enough to conclude that the drug works.\nBut the FDA granted conditional approval to the drug on Monday (June 7), on the basis that it could remove a bad protein called amyloid from the brain.\nThe decision \"was probably the worst drug approval decision in recent US history,\" Dr Kesselheim said in the letter. \"The agency owes it to the nation to provide a detailed justification\" for going against the advice of the panel, he said.\nDuring the November advisory committee meeting, concerns about the data \"were not given adequate time for discussion\" and the crucial question of whether an Alzheimer's drug should be approved based on amyloid lowering alone \"was specifically excluded from discussion,\" Dr Kesselheim wrote.\nThe doctor also made broader criticisms of the agency, saying it needed to reassess its decision-making process.\nDr Kesselheim is the third member to quit the committee, following Joel Perlmutter from the Washington University School of Medicine and David Knopman from the Mayo Clinic. Both Dr Perlmutter and Dr Kesselheim voted against the drug, while Dr Knopman was recused from the November hearing as he had already staked out a public position critical of the drug's trial results.\nDr Perlmutter resigned \"due to the FDA approval of aducanumab without further discussion with the advisory panel,\" a spokeswoman for Washington University said in an e-mail.\nDr Knopman's resignation was confirmed by the Mayo Clinic.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":181382876,"gmtCreate":1623374224195,"gmtModify":1704201931430,"author":{"id":"3571697757751706","authorId":"3571697757751706","name":"JamesPang","avatar":"https://community-static.tradeup.com/news/936d6e2f7f57e8860a9bdfab91b7f40e","vip":1,"hat":"https://static.tigerbbs.com/0a8758340a08196056f8bc1e54805193","crmLevel":4,"crmLevelSwitch":0,"idStr":"3571697757751706","authorIdStr":"3571697757751706"},"htmlText":"That is the problem with government agency.. they think they know everything","listText":"That is the problem with government agency.. they think they know everything","text":"That is the problem with government agency.. they think they know everything","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/181382876","repostId":2142346278,"repostType":4,"repost":{"id":"2142346278","pubTimestamp":1623372873,"share":"https://ttm.financial/m/news/2142346278?lang=&edition=fundamental","pubTime":"2021-06-11 08:54","market":"us","language":"en","title":"Harvard expert quits US FDA panel as furore over Biogen's Alzheimer's drug grows","url":"https://stock-news.laohu8.com/highlight/detail?id=2142346278","media":"The Straits Times","summary":"WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food an","content":"<div>\n<p>WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food and Drug Administration advisory panel in protest over the agency's decision to approve Biogen's ...</p>\n\n<a href=\"http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows\">Web Link</a>\n\n</div>\n","source":"straits_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Harvard expert quits US FDA panel as furore over Biogen's Alzheimer's drug grows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHarvard expert quits US FDA panel as furore over Biogen's Alzheimer's drug grows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 08:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows><strong>The Straits Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food and Drug Administration advisory panel in protest over the agency's decision to approve Biogen's ...</p>\n\n<a href=\"http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142346278","content_text":"WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food and Drug Administration advisory panel in protest over the agency's decision to approve Biogen's Alzheimer's drug Aduhelm.\nThe doctor, Aaron Kesselheim, announced his departure in a letter to FDA Acting Commissioner Janet Woodcock. He is the third committee member to quit in the wake of the highly controversial approval.\nTwo big trials of the drug produced conflicting results on whether it could slow cognitive decline. The advisory panel voted almost unanimously in November that a single trial wasn't enough to conclude that the drug works.\nBut the FDA granted conditional approval to the drug on Monday (June 7), on the basis that it could remove a bad protein called amyloid from the brain.\nThe decision \"was probably the worst drug approval decision in recent US history,\" Dr Kesselheim said in the letter. \"The agency owes it to the nation to provide a detailed justification\" for going against the advice of the panel, he said.\nDuring the November advisory committee meeting, concerns about the data \"were not given adequate time for discussion\" and the crucial question of whether an Alzheimer's drug should be approved based on amyloid lowering alone \"was specifically excluded from discussion,\" Dr Kesselheim wrote.\nThe doctor also made broader criticisms of the agency, saying it needed to reassess its decision-making process.\nDr Kesselheim is the third member to quit the committee, following Joel Perlmutter from the Washington University School of Medicine and David Knopman from the Mayo Clinic. Both Dr Perlmutter and Dr Kesselheim voted against the drug, while Dr Knopman was recused from the November hearing as he had already staked out a public position critical of the drug's trial results.\nDr Perlmutter resigned \"due to the FDA approval of aducanumab without further discussion with the advisory panel,\" a spokeswoman for Washington University said in an e-mail.\nDr Knopman's resignation was confirmed by the Mayo Clinic.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":181388151,"gmtCreate":1623374135273,"gmtModify":1704201928155,"author":{"id":"3571641801586244","authorId":"3571641801586244","name":"Lanying","avatar":"https://static.tigerbbs.com/44079e6feb39117800ea99462f8cae40","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3571641801586244","authorIdStr":"3571641801586244"},"htmlText":"O","listText":"O","text":"O","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/181388151","repostId":2142346278,"repostType":4,"repost":{"id":"2142346278","pubTimestamp":1623372873,"share":"https://ttm.financial/m/news/2142346278?lang=&edition=fundamental","pubTime":"2021-06-11 08:54","market":"us","language":"en","title":"Harvard expert quits US FDA panel as furore over Biogen's Alzheimer's drug grows","url":"https://stock-news.laohu8.com/highlight/detail?id=2142346278","media":"The Straits Times","summary":"WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food an","content":"<div>\n<p>WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food and Drug Administration advisory panel in protest over the agency's decision to approve Biogen's ...</p>\n\n<a href=\"http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows\">Web Link</a>\n\n</div>\n","source":"straits_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Harvard expert quits US FDA panel as furore over Biogen's Alzheimer's drug grows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHarvard expert quits US FDA panel as furore over Biogen's Alzheimer's drug grows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 08:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows><strong>The Straits Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food and Drug Administration advisory panel in protest over the agency's decision to approve Biogen's ...</p>\n\n<a href=\"http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142346278","content_text":"WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food and Drug Administration advisory panel in protest over the agency's decision to approve Biogen's Alzheimer's drug Aduhelm.\nThe doctor, Aaron Kesselheim, announced his departure in a letter to FDA Acting Commissioner Janet Woodcock. He is the third committee member to quit in the wake of the highly controversial approval.\nTwo big trials of the drug produced conflicting results on whether it could slow cognitive decline. The advisory panel voted almost unanimously in November that a single trial wasn't enough to conclude that the drug works.\nBut the FDA granted conditional approval to the drug on Monday (June 7), on the basis that it could remove a bad protein called amyloid from the brain.\nThe decision \"was probably the worst drug approval decision in recent US history,\" Dr Kesselheim said in the letter. \"The agency owes it to the nation to provide a detailed justification\" for going against the advice of the panel, he said.\nDuring the November advisory committee meeting, concerns about the data \"were not given adequate time for discussion\" and the crucial question of whether an Alzheimer's drug should be approved based on amyloid lowering alone \"was specifically excluded from discussion,\" Dr Kesselheim wrote.\nThe doctor also made broader criticisms of the agency, saying it needed to reassess its decision-making process.\nDr Kesselheim is the third member to quit the committee, following Joel Perlmutter from the Washington University School of Medicine and David Knopman from the Mayo Clinic. Both Dr Perlmutter and Dr Kesselheim voted against the drug, while Dr Knopman was recused from the November hearing as he had already staked out a public position critical of the drug's trial results.\nDr Perlmutter resigned \"due to the FDA approval of aducanumab without further discussion with the advisory panel,\" a spokeswoman for Washington University said in an e-mail.\nDr Knopman's resignation was confirmed by the Mayo Clinic.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4676334,"gmtCreate":1623374145606,"gmtModify":1663228414526,"authorId":3571641801586244,"author":{"id":3571641801586244,"idStr":"3571641801586244","authorId":3571641801586244,"name":"Lanying","avatar":"https://static.tigerbbs.com/44079e6feb39117800ea99462f8cae40","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":181388151,"type":1,"supId":0,"prevId":0,"content":"O","text":"O","html":"O"}],"langContent":"EN"},{"id":181380658,"gmtCreate":1623373932274,"gmtModify":1704201923304,"author":{"id":"3579391265651951","authorId":"3579391265651951","name":"CharlesKing","avatar":"https://static.tigerbbs.com/d8fbdcf3295ba7f84c1f2205610ea968","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3579391265651951","authorIdStr":"3579391265651951"},"htmlText":"Like and comment plz???","listText":"Like and comment plz???","text":"Like and comment plz???","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/181380658","repostId":2142346278,"repostType":4,"repost":{"id":"2142346278","pubTimestamp":1623372873,"share":"https://ttm.financial/m/news/2142346278?lang=&edition=fundamental","pubTime":"2021-06-11 08:54","market":"us","language":"en","title":"Harvard expert quits US FDA panel as furore over Biogen's Alzheimer's drug grows","url":"https://stock-news.laohu8.com/highlight/detail?id=2142346278","media":"The Straits Times","summary":"WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food an","content":"<div>\n<p>WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food and Drug Administration advisory panel in protest over the agency's decision to approve Biogen's ...</p>\n\n<a href=\"http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows\">Web Link</a>\n\n</div>\n","source":"straits_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Harvard expert quits US FDA panel as furore over Biogen's Alzheimer's drug grows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHarvard expert quits US FDA panel as furore over Biogen's Alzheimer's drug grows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 08:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows><strong>The Straits Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food and Drug Administration advisory panel in protest over the agency's decision to approve Biogen's ...</p>\n\n<a href=\"http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142346278","content_text":"WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food and Drug Administration advisory panel in protest over the agency's decision to approve Biogen's Alzheimer's drug Aduhelm.\nThe doctor, Aaron Kesselheim, announced his departure in a letter to FDA Acting Commissioner Janet Woodcock. He is the third committee member to quit in the wake of the highly controversial approval.\nTwo big trials of the drug produced conflicting results on whether it could slow cognitive decline. The advisory panel voted almost unanimously in November that a single trial wasn't enough to conclude that the drug works.\nBut the FDA granted conditional approval to the drug on Monday (June 7), on the basis that it could remove a bad protein called amyloid from the brain.\nThe decision \"was probably the worst drug approval decision in recent US history,\" Dr Kesselheim said in the letter. \"The agency owes it to the nation to provide a detailed justification\" for going against the advice of the panel, he said.\nDuring the November advisory committee meeting, concerns about the data \"were not given adequate time for discussion\" and the crucial question of whether an Alzheimer's drug should be approved based on amyloid lowering alone \"was specifically excluded from discussion,\" Dr Kesselheim wrote.\nThe doctor also made broader criticisms of the agency, saying it needed to reassess its decision-making process.\nDr Kesselheim is the third member to quit the committee, following Joel Perlmutter from the Washington University School of Medicine and David Knopman from the Mayo Clinic. Both Dr Perlmutter and Dr Kesselheim voted against the drug, while Dr Knopman was recused from the November hearing as he had already staked out a public position critical of the drug's trial results.\nDr Perlmutter resigned \"due to the FDA approval of aducanumab without further discussion with the advisory panel,\" a spokeswoman for Washington University said in an e-mail.\nDr Knopman's resignation was confirmed by the Mayo Clinic.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4676554,"gmtCreate":1623374793964,"gmtModify":1663228416932,"authorId":3577229760496516,"author":{"id":3577229760496516,"idStr":"3577229760496516","authorId":3577229760496516,"name":"木吉蒂","avatar":"https://static.tigerbbs.com/89290f2c42589f1e42296c61dde71238","vip":1,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.11.22","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1001},"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":181380658,"type":1,"supId":0,"prevId":0,"content":"done","text":"done","html":"done"}],"langContent":"EN"},{"id":181316874,"gmtCreate":1623373768898,"gmtModify":1704201916491,"author":{"id":"3579045920422452","authorId":"3579045920422452","name":"GCL08","avatar":"https://static.tigerbbs.com/3433a6063e0b2ab82ed571a0790eb790","vip":1,"crmLevel":2,"crmLevelSwitch":1,"idStr":"3579045920422452","authorIdStr":"3579045920422452"},"htmlText":"Respect to stick to do the right thing for a better world rather for companies to make a quick buck by approving drugs that are not ready ??❤️?✌️","listText":"Respect to stick to do the right thing for a better world rather for companies to make a quick buck by approving drugs that are not ready ??❤️?✌️","text":"Respect to stick to do the right thing for a better world rather for companies to make a quick buck by approving drugs that are not ready ??❤️?✌️","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/181316874","repostId":2142346278,"repostType":4,"repost":{"id":"2142346278","pubTimestamp":1623372873,"share":"https://ttm.financial/m/news/2142346278?lang=&edition=fundamental","pubTime":"2021-06-11 08:54","market":"us","language":"en","title":"Harvard expert quits US FDA panel as furore over Biogen's Alzheimer's drug grows","url":"https://stock-news.laohu8.com/highlight/detail?id=2142346278","media":"The Straits Times","summary":"WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food an","content":"<div>\n<p>WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food and Drug Administration advisory panel in protest over the agency's decision to approve Biogen's ...</p>\n\n<a href=\"http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows\">Web Link</a>\n\n</div>\n","source":"straits_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Harvard expert quits US FDA panel as furore over Biogen's Alzheimer's drug grows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHarvard expert quits US FDA panel as furore over Biogen's Alzheimer's drug grows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 08:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows><strong>The Straits Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food and Drug Administration advisory panel in protest over the agency's decision to approve Biogen's ...</p>\n\n<a href=\"http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142346278","content_text":"WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food and Drug Administration advisory panel in protest over the agency's decision to approve Biogen's Alzheimer's drug Aduhelm.\nThe doctor, Aaron Kesselheim, announced his departure in a letter to FDA Acting Commissioner Janet Woodcock. He is the third committee member to quit in the wake of the highly controversial approval.\nTwo big trials of the drug produced conflicting results on whether it could slow cognitive decline. The advisory panel voted almost unanimously in November that a single trial wasn't enough to conclude that the drug works.\nBut the FDA granted conditional approval to the drug on Monday (June 7), on the basis that it could remove a bad protein called amyloid from the brain.\nThe decision \"was probably the worst drug approval decision in recent US history,\" Dr Kesselheim said in the letter. \"The agency owes it to the nation to provide a detailed justification\" for going against the advice of the panel, he said.\nDuring the November advisory committee meeting, concerns about the data \"were not given adequate time for discussion\" and the crucial question of whether an Alzheimer's drug should be approved based on amyloid lowering alone \"was specifically excluded from discussion,\" Dr Kesselheim wrote.\nThe doctor also made broader criticisms of the agency, saying it needed to reassess its decision-making process.\nDr Kesselheim is the third member to quit the committee, following Joel Perlmutter from the Washington University School of Medicine and David Knopman from the Mayo Clinic. Both Dr Perlmutter and Dr Kesselheim voted against the drug, while Dr Knopman was recused from the November hearing as he had already staked out a public position critical of the drug's trial results.\nDr Perlmutter resigned \"due to the FDA approval of aducanumab without further discussion with the advisory panel,\" a spokeswoman for Washington University said in an e-mail.\nDr Knopman's resignation was confirmed by the Mayo Clinic.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4676239,"gmtCreate":1623373829117,"gmtModify":1663228415931,"authorId":3581385014673304,"author":{"id":3581385014673304,"idStr":"3581385014673304","authorId":3581385014673304,"name":"Qkuca","avatar":"https://static.tigerbbs.com/69a0785cbfa53d9d0452a1870c401782","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":181316874,"type":1,"supId":0,"prevId":0,"content":"[微笑]","text":"[微笑]","html":"[微笑]"}],"langContent":"EN"},{"id":181319100,"gmtCreate":1623373598700,"gmtModify":1704201910432,"author":{"id":"3581719514650082","authorId":"3581719514650082","name":"nickname223","avatar":"https://static.tigerbbs.com/3c9d3ce9ebd1f38f8f9c780ce1096cdd","vip":1,"hat":"https://static.tigerbbs.com/a3dee1aa3a3a3c1814833a4d3f8a5669","crmLevel":2,"crmLevelSwitch":1,"idStr":"3581719514650082","authorIdStr":"3581719514650082"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/181319100","repostId":2142346278,"repostType":4,"repost":{"id":"2142346278","pubTimestamp":1623372873,"share":"https://ttm.financial/m/news/2142346278?lang=&edition=fundamental","pubTime":"2021-06-11 08:54","market":"us","language":"en","title":"Harvard expert quits US FDA panel as furore over Biogen's Alzheimer's drug grows","url":"https://stock-news.laohu8.com/highlight/detail?id=2142346278","media":"The Straits Times","summary":"WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food an","content":"<div>\n<p>WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food and Drug Administration advisory panel in protest over the agency's decision to approve Biogen's ...</p>\n\n<a href=\"http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows\">Web Link</a>\n\n</div>\n","source":"straits_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Harvard expert quits US FDA panel as furore over Biogen's Alzheimer's drug grows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHarvard expert quits US FDA panel as furore over Biogen's Alzheimer's drug grows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 08:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows><strong>The Straits Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food and Drug Administration advisory panel in protest over the agency's decision to approve Biogen's ...</p>\n\n<a href=\"http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142346278","content_text":"WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food and Drug Administration advisory panel in protest over the agency's decision to approve Biogen's Alzheimer's drug Aduhelm.\nThe doctor, Aaron Kesselheim, announced his departure in a letter to FDA Acting Commissioner Janet Woodcock. He is the third committee member to quit in the wake of the highly controversial approval.\nTwo big trials of the drug produced conflicting results on whether it could slow cognitive decline. The advisory panel voted almost unanimously in November that a single trial wasn't enough to conclude that the drug works.\nBut the FDA granted conditional approval to the drug on Monday (June 7), on the basis that it could remove a bad protein called amyloid from the brain.\nThe decision \"was probably the worst drug approval decision in recent US history,\" Dr Kesselheim said in the letter. \"The agency owes it to the nation to provide a detailed justification\" for going against the advice of the panel, he said.\nDuring the November advisory committee meeting, concerns about the data \"were not given adequate time for discussion\" and the crucial question of whether an Alzheimer's drug should be approved based on amyloid lowering alone \"was specifically excluded from discussion,\" Dr Kesselheim wrote.\nThe doctor also made broader criticisms of the agency, saying it needed to reassess its decision-making process.\nDr Kesselheim is the third member to quit the committee, following Joel Perlmutter from the Washington University School of Medicine and David Knopman from the Mayo Clinic. Both Dr Perlmutter and Dr Kesselheim voted against the drug, while Dr Knopman was recused from the November hearing as he had already staked out a public position critical of the drug's trial results.\nDr Perlmutter resigned \"due to the FDA approval of aducanumab without further discussion with the advisory panel,\" a spokeswoman for Washington University said in an e-mail.\nDr Knopman's resignation was confirmed by the Mayo Clinic.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":181335650,"gmtCreate":1623373457770,"gmtModify":1704201905021,"author":{"id":"3576284335652964","authorId":"3576284335652964","name":"Dickson8614","avatar":"https://static.tigerbbs.com/1c6a81e28879ea087b93c6234e7b7eb8","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":6,"crmLevelSwitch":1,"idStr":"3576284335652964","authorIdStr":"3576284335652964"},"htmlText":"Please like and comment","listText":"Please like and comment","text":"Please like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/181335650","repostId":2142346278,"repostType":4,"repost":{"id":"2142346278","pubTimestamp":1623372873,"share":"https://ttm.financial/m/news/2142346278?lang=&edition=fundamental","pubTime":"2021-06-11 08:54","market":"us","language":"en","title":"Harvard expert quits US FDA panel as furore over Biogen's Alzheimer's drug grows","url":"https://stock-news.laohu8.com/highlight/detail?id=2142346278","media":"The Straits Times","summary":"WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food an","content":"<div>\n<p>WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food and Drug Administration advisory panel in protest over the agency's decision to approve Biogen's ...</p>\n\n<a href=\"http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows\">Web Link</a>\n\n</div>\n","source":"straits_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Harvard expert quits US FDA panel as furore over Biogen's Alzheimer's drug grows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHarvard expert quits US FDA panel as furore over Biogen's Alzheimer's drug grows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 08:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows><strong>The Straits Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food and Drug Administration advisory panel in protest over the agency's decision to approve Biogen's ...</p>\n\n<a href=\"http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142346278","content_text":"WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food and Drug Administration advisory panel in protest over the agency's decision to approve Biogen's Alzheimer's drug Aduhelm.\nThe doctor, Aaron Kesselheim, announced his departure in a letter to FDA Acting Commissioner Janet Woodcock. He is the third committee member to quit in the wake of the highly controversial approval.\nTwo big trials of the drug produced conflicting results on whether it could slow cognitive decline. The advisory panel voted almost unanimously in November that a single trial wasn't enough to conclude that the drug works.\nBut the FDA granted conditional approval to the drug on Monday (June 7), on the basis that it could remove a bad protein called amyloid from the brain.\nThe decision \"was probably the worst drug approval decision in recent US history,\" Dr Kesselheim said in the letter. \"The agency owes it to the nation to provide a detailed justification\" for going against the advice of the panel, he said.\nDuring the November advisory committee meeting, concerns about the data \"were not given adequate time for discussion\" and the crucial question of whether an Alzheimer's drug should be approved based on amyloid lowering alone \"was specifically excluded from discussion,\" Dr Kesselheim wrote.\nThe doctor also made broader criticisms of the agency, saying it needed to reassess its decision-making process.\nDr Kesselheim is the third member to quit the committee, following Joel Perlmutter from the Washington University School of Medicine and David Knopman from the Mayo Clinic. Both Dr Perlmutter and Dr Kesselheim voted against the drug, while Dr Knopman was recused from the November hearing as he had already staked out a public position critical of the drug's trial results.\nDr Perlmutter resigned \"due to the FDA approval of aducanumab without further discussion with the advisory panel,\" a spokeswoman for Washington University said in an e-mail.\nDr Knopman's resignation was confirmed by the Mayo Clinic.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4676121,"gmtCreate":1623373607461,"gmtModify":1663228414433,"authorId":3581719514650082,"author":{"id":3581719514650082,"idStr":"3581719514650082","authorId":3581719514650082,"name":"nickname223","avatar":"https://static.tigerbbs.com/3c9d3ce9ebd1f38f8f9c780ce1096cdd","vip":1,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-1","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Debut Tiger","description":"Join the tiger community for 500 days","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.08.31","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1001},"crmLevel":2,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":181335650,"type":1,"supId":0,"prevId":0,"content":"<u>loke</u>","text":"<u>loke</u>","html":"<u>loke</u>"},{"id":4676090,"gmtCreate":1623373521866,"gmtModify":1663228414341,"authorId":3581982441889617,"author":{"id":3581982441889617,"idStr":"3581982441889617","authorId":3581982441889617,"name":"edamame","avatar":"https://static.tigerbbs.com/63449ce6bfbebf6849034560328a7d39","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":181335650,"type":1,"supId":0,"prevId":0,"content":"<u>up</u>","text":"<u>up</u>","html":"<u>up</u>"}],"langContent":"EN"},{"id":181335973,"gmtCreate":1623373435292,"gmtModify":1704201904207,"author":{"id":"3555205938335288","authorId":"3555205938335288","name":"Mayvee","avatar":"https://static.tigerbbs.com/066ac4fb3104fc9b6fd24f899a1ee86f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3555205938335288","authorIdStr":"3555205938335288"},"htmlText":"Must be a subjective type of decision made for the approval hence a resignation took place.","listText":"Must be a subjective type of decision made for the approval hence a resignation took place.","text":"Must be a subjective type of decision made for the approval hence a resignation took place.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/181335973","repostId":2142346278,"repostType":4,"repost":{"id":"2142346278","pubTimestamp":1623372873,"share":"https://ttm.financial/m/news/2142346278?lang=&edition=fundamental","pubTime":"2021-06-11 08:54","market":"us","language":"en","title":"Harvard expert quits US FDA panel as furore over Biogen's Alzheimer's drug grows","url":"https://stock-news.laohu8.com/highlight/detail?id=2142346278","media":"The Straits Times","summary":"WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food an","content":"<div>\n<p>WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food and Drug Administration advisory panel in protest over the agency's decision to approve Biogen's ...</p>\n\n<a href=\"http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows\">Web Link</a>\n\n</div>\n","source":"straits_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Harvard expert quits US FDA panel as furore over Biogen's Alzheimer's drug grows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHarvard expert quits US FDA panel as furore over Biogen's Alzheimer's drug grows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 08:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows><strong>The Straits Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food and Drug Administration advisory panel in protest over the agency's decision to approve Biogen's ...</p>\n\n<a href=\"http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142346278","content_text":"WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food and Drug Administration advisory panel in protest over the agency's decision to approve Biogen's Alzheimer's drug Aduhelm.\nThe doctor, Aaron Kesselheim, announced his departure in a letter to FDA Acting Commissioner Janet Woodcock. He is the third committee member to quit in the wake of the highly controversial approval.\nTwo big trials of the drug produced conflicting results on whether it could slow cognitive decline. The advisory panel voted almost unanimously in November that a single trial wasn't enough to conclude that the drug works.\nBut the FDA granted conditional approval to the drug on Monday (June 7), on the basis that it could remove a bad protein called amyloid from the brain.\nThe decision \"was probably the worst drug approval decision in recent US history,\" Dr Kesselheim said in the letter. \"The agency owes it to the nation to provide a detailed justification\" for going against the advice of the panel, he said.\nDuring the November advisory committee meeting, concerns about the data \"were not given adequate time for discussion\" and the crucial question of whether an Alzheimer's drug should be approved based on amyloid lowering alone \"was specifically excluded from discussion,\" Dr Kesselheim wrote.\nThe doctor also made broader criticisms of the agency, saying it needed to reassess its decision-making process.\nDr Kesselheim is the third member to quit the committee, following Joel Perlmutter from the Washington University School of Medicine and David Knopman from the Mayo Clinic. Both Dr Perlmutter and Dr Kesselheim voted against the drug, while Dr Knopman was recused from the November hearing as he had already staked out a public position critical of the drug's trial results.\nDr Perlmutter resigned \"due to the FDA approval of aducanumab without further discussion with the advisory panel,\" a spokeswoman for Washington University said in an e-mail.\nDr Knopman's resignation was confirmed by the Mayo Clinic.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4676243,"gmtCreate":1623373841074,"gmtModify":1663228416046,"authorId":3581385014673304,"author":{"id":3581385014673304,"idStr":"3581385014673304","authorId":3581385014673304,"name":"Qkuca","avatar":"https://static.tigerbbs.com/69a0785cbfa53d9d0452a1870c401782","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":181335973,"type":1,"supId":0,"prevId":0,"content":"[微笑]","text":"[微笑]","html":"[微笑]"}],"langContent":"EN"},{"id":181332790,"gmtCreate":1623373431010,"gmtModify":1704201903881,"author":{"id":"3581982441889617","authorId":"3581982441889617","name":"edamame","avatar":"https://static.tigerbbs.com/63449ce6bfbebf6849034560328a7d39","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581982441889617","authorIdStr":"3581982441889617"},"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/181332790","repostId":2142346278,"repostType":4,"repost":{"id":"2142346278","pubTimestamp":1623372873,"share":"https://ttm.financial/m/news/2142346278?lang=&edition=fundamental","pubTime":"2021-06-11 08:54","market":"us","language":"en","title":"Harvard expert quits US FDA panel as furore over Biogen's Alzheimer's drug grows","url":"https://stock-news.laohu8.com/highlight/detail?id=2142346278","media":"The Straits Times","summary":"WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food an","content":"<div>\n<p>WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food and Drug Administration advisory panel in protest over the agency's decision to approve Biogen's ...</p>\n\n<a href=\"http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows\">Web Link</a>\n\n</div>\n","source":"straits_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Harvard expert quits US FDA panel as furore over Biogen's Alzheimer's drug grows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHarvard expert quits US FDA panel as furore over Biogen's Alzheimer's drug grows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 08:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows><strong>The Straits Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food and Drug Administration advisory panel in protest over the agency's decision to approve Biogen's ...</p>\n\n<a href=\"http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142346278","content_text":"WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food and Drug Administration advisory panel in protest over the agency's decision to approve Biogen's Alzheimer's drug Aduhelm.\nThe doctor, Aaron Kesselheim, announced his departure in a letter to FDA Acting Commissioner Janet Woodcock. He is the third committee member to quit in the wake of the highly controversial approval.\nTwo big trials of the drug produced conflicting results on whether it could slow cognitive decline. The advisory panel voted almost unanimously in November that a single trial wasn't enough to conclude that the drug works.\nBut the FDA granted conditional approval to the drug on Monday (June 7), on the basis that it could remove a bad protein called amyloid from the brain.\nThe decision \"was probably the worst drug approval decision in recent US history,\" Dr Kesselheim said in the letter. \"The agency owes it to the nation to provide a detailed justification\" for going against the advice of the panel, he said.\nDuring the November advisory committee meeting, concerns about the data \"were not given adequate time for discussion\" and the crucial question of whether an Alzheimer's drug should be approved based on amyloid lowering alone \"was specifically excluded from discussion,\" Dr Kesselheim wrote.\nThe doctor also made broader criticisms of the agency, saying it needed to reassess its decision-making process.\nDr Kesselheim is the third member to quit the committee, following Joel Perlmutter from the Washington University School of Medicine and David Knopman from the Mayo Clinic. Both Dr Perlmutter and Dr Kesselheim voted against the drug, while Dr Knopman was recused from the November hearing as he had already staked out a public position critical of the drug's trial results.\nDr Perlmutter resigned \"due to the FDA approval of aducanumab without further discussion with the advisory panel,\" a spokeswoman for Washington University said in an e-mail.\nDr Knopman's resignation was confirmed by the Mayo Clinic.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":181330340,"gmtCreate":1623373104380,"gmtModify":1704201895809,"author":{"id":"3581972561289020","authorId":"3581972561289020","name":"Sena11","avatar":"https://static.tigerbbs.com/332d7d74927168702f2c7c17483c8a6a","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3581972561289020","authorIdStr":"3581972561289020"},"htmlText":"Pls like","listText":"Pls like","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/181330340","repostId":2142346278,"repostType":4,"repost":{"id":"2142346278","pubTimestamp":1623372873,"share":"https://ttm.financial/m/news/2142346278?lang=&edition=fundamental","pubTime":"2021-06-11 08:54","market":"us","language":"en","title":"Harvard expert quits US FDA panel as furore over Biogen's Alzheimer's drug grows","url":"https://stock-news.laohu8.com/highlight/detail?id=2142346278","media":"The Straits Times","summary":"WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food an","content":"<div>\n<p>WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food and Drug Administration advisory panel in protest over the agency's decision to approve Biogen's ...</p>\n\n<a href=\"http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows\">Web Link</a>\n\n</div>\n","source":"straits_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Harvard expert quits US FDA panel as furore over Biogen's Alzheimer's drug grows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHarvard expert quits US FDA panel as furore over Biogen's Alzheimer's drug grows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 08:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows><strong>The Straits Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food and Drug Administration advisory panel in protest over the agency's decision to approve Biogen's ...</p>\n\n<a href=\"http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"http://www.straitstimes.com/world/united-states/harvard-expert-quits-us-fda-panel-as-furore-over-biogens-alzheimer-drug-grows","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142346278","content_text":"WASHINGTON (BLOOMBERG) - A prominent Harvard Medical School professor has resigned from a US Food and Drug Administration advisory panel in protest over the agency's decision to approve Biogen's Alzheimer's drug Aduhelm.\nThe doctor, Aaron Kesselheim, announced his departure in a letter to FDA Acting Commissioner Janet Woodcock. He is the third committee member to quit in the wake of the highly controversial approval.\nTwo big trials of the drug produced conflicting results on whether it could slow cognitive decline. The advisory panel voted almost unanimously in November that a single trial wasn't enough to conclude that the drug works.\nBut the FDA granted conditional approval to the drug on Monday (June 7), on the basis that it could remove a bad protein called amyloid from the brain.\nThe decision \"was probably the worst drug approval decision in recent US history,\" Dr Kesselheim said in the letter. \"The agency owes it to the nation to provide a detailed justification\" for going against the advice of the panel, he said.\nDuring the November advisory committee meeting, concerns about the data \"were not given adequate time for discussion\" and the crucial question of whether an Alzheimer's drug should be approved based on amyloid lowering alone \"was specifically excluded from discussion,\" Dr Kesselheim wrote.\nThe doctor also made broader criticisms of the agency, saying it needed to reassess its decision-making process.\nDr Kesselheim is the third member to quit the committee, following Joel Perlmutter from the Washington University School of Medicine and David Knopman from the Mayo Clinic. Both Dr Perlmutter and Dr Kesselheim voted against the drug, while Dr Knopman was recused from the November hearing as he had already staked out a public position critical of the drug's trial results.\nDr Perlmutter resigned \"due to the FDA approval of aducanumab without further discussion with the advisory panel,\" a spokeswoman for Washington University said in an e-mail.\nDr Knopman's resignation was confirmed by the Mayo Clinic.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4683257,"gmtCreate":1623401250102,"gmtModify":1663228449126,"authorId":3581972561289020,"author":{"id":3581972561289020,"idStr":"3581972561289020","authorId":3581972561289020,"name":"Sena11","avatar":"https://static.tigerbbs.com/332d7d74927168702f2c7c17483c8a6a","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":181330340,"type":1,"supId":4676071,"prevId":0,"content":"Thank","text":"Thank","html":"Thank"},{"id":4676066,"gmtCreate":1623373440493,"gmtModify":1663228414631,"authorId":3581982441889617,"author":{"id":3581982441889617,"idStr":"3581982441889617","authorId":3581982441889617,"name":"edamame","avatar":"https://static.tigerbbs.com/63449ce6bfbebf6849034560328a7d39","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":181330340,"type":1,"supId":0,"prevId":0,"content":"<u>up</u>","text":"<u>up</u>","html":"<u>up</u>"},{"id":4676071,"gmtCreate":1623373452974,"gmtModify":1663228414629,"authorId":3583037256607811,"author":{"id":3583037256607811,"idStr":"3583037256607811","authorId":3583037256607811,"name":"TeckLeong","avatar":"https://static.tigerbbs.com/8ab4cb02daedd7a5193ca45de25e12fe","vip":1,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.22","exceedPercentage":"60.99%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1101},"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":181330340,"type":1,"supId":0,"prevId":0,"content":"Pls like aNd comMent back","text":"Pls like aNd comMent back","html":"Pls like aNd comMent back"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":61,"commentSize":17,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}